Summary
Gilead Sciences, Inc. (GILD) has filed a Current Report (8-K) on February 2, 2023, to announce its financial results for the fourth quarter and full year ended December 31, 2022. The filing includes a press release detailing these results, which were presented on both a GAAP and non-GAAP basis. Management believes the non-GAAP information provides useful insights for investors, aiding in the understanding of the company's operational performance and financial planning. Investors should refer to the press release (Exhibit 99.1) for a comprehensive overview of Gilead's financial performance, including a reconciliation of non-GAAP measures to GAAP. The company emphasizes that non-GAAP financial information should be used to supplement, not replace, the understanding of GAAP-reported results and that definitions may vary among industry peers.
Key Highlights
- 1Gilead Sciences announced its Q4 and full-year 2022 financial results via an 8-K filing on February 2, 2023.
- 2The financial results were presented using both U.S. Generally Accepted Accounting Principles (GAAP) and non-GAAP measures.
- 3Management considers non-GAAP financial information valuable for investors, aiding in operational and financial planning insights.
- 4A detailed reconciliation between GAAP and non-GAAP financial information is available in the press release.
- 5The press release, issued on February 2, 2023, serves as Exhibit 99.1 to the 8-K filing.
- 6The information provided in this filing, particularly regarding financial results, is not considered 'filed' for Section 18 purposes of the Exchange Act.